Diabetes drugs pass cardiovascular risk check

  • Alisa Opar
  • Published 2009 in Nature Reviews Drug Discovery


Although the first two investigational anti-diabetic drugs to be assessed for increased cardiovascular risk by the US FDA are unlikely to require additional clinical trials before approval, companies are actively adapting their preclinical and clinical development programmes in response to last year's FDA guidance.

DOI: 10.1038/nrd2890

Cite this paper

@article{Opar2009DiabetesDP, title={Diabetes drugs pass cardiovascular risk check}, author={Alisa Opar}, journal={Nature Reviews Drug Discovery}, year={2009}, volume={8}, pages={343-344} }